Is Gardnerella Vaginalis a Sexually Transmitted Disease?

Gardnerella vaginalis is not classified as a sexually transmitted disease in any major clinical guideline, yet growing evidence shows it can be passed between sexual partners and that sexual activity is one of the strongest risk factors for the condition it causes, bacterial vaginosis (BV). The honest answer is that this bacterium lives in a gray zone: it behaves like an STI in many respects but breaks the rules of that category in others. That gray zone matters, because it shapes how doctors treat the condition, whether partners get treated, and how much stigma patients carry.

Why the Classification Has Always Been Awkward

Gardnerella vaginalis was first identified in 1953, and researchers have been debating its role in vaginal infections ever since. It was eventually recognized as the organism most consistently associated with BV, the most common cause of abnormal vaginal discharge worldwide. But calling something an STI typically requires that the infection is primarily transmitted through sexual contact and that treating partners prevents reinfection. G. vaginalis does not fit neatly into either criterion.

The CDC includes BV in its sexually transmitted infections treatment guidelines, reflecting the strong epidemiological link between BV and sexual behavior. The evidence reviewed for the 2021 guidelines specifically highlighted “data supportive of sexual transmission of BV-associated bacteria” as a key focus area.¹ Yet the same guidelines stop short of recommending routine partner treatment, and BV is consistently described as “associated with” rather than “caused by” sexual transmission. That careful wording reflects genuine scientific uncertainty, not bureaucratic hedging.

The Case for Sexual Transmission

Several lines of evidence point firmly toward sex as a major transmission route. Consistent condom use has been shown to cut the odds of developing BV by roughly half among women without BV at baseline.² A separate study found that among women who already had BV, condoms made little difference, but among women who were BV-free at enrollment, consistent condom use reduced the likelihood of developing BV by about 40%.³ That pattern makes sense if sexual contact introduces the bacteria but condoms cannot clear an existing infection.

Epidemiological reviews have noted that G. vaginalis carriage is enhanced not only by penetrative sex but also by non-penetrative digital-genital contact and oral sex, suggesting that sexual contact broadly, not just intercourse specifically, facilitates transmission.⁴ Male partners can harbor G. vaginalis in semen even when urethral cultures come back negative. In one documented case, a man whose urethra tested clear for the bacterium was found to carry it in his semen, and his female partner’s recurrent BV resolved only after he was treated with antibiotics.⁵

G. vaginalis can also form biofilms on the penile skin and in the male genital tract, which may serve as a reservoir for reinfecting a female partner after she finishes treatment. This biofilm formation is part of the reason BV recurs so often: the bacteria create a structured community that shields them from both the immune system and antibiotics.⁶

What Studies of Women Who Have Sex With Women Reveal

Some of the most compelling evidence for sexual transmission comes from research on women who have sex with women (WSW). If BV were purely a consequence of exposure to semen or the penile microbiome, you would expect low rates among WSW. Instead, studies consistently find high rates of BV in this population, and the rates track closely with specific sexual behaviors.

Women reporting sex with a new female partner were roughly three and a half times more likely to have a vaginal microbiome dominated by G. vaginalis compared with women who had no new partner, even after adjusting for other factors.⁷ Research into the different genetic clades of G. vaginalis has found that certain clades are associated with recent sexual practices and BV symptoms, while others are widespread but seemingly harmless. Clade 1, for example, was the only clade linked to both BV diagnosis and a lactobacillus-deficient vaginal environment, while clade 4 was the most common overall but was not associated with BV.⁸ The fact that different clades circulate through different sexual networks strongly suggests that sexual contact is a real transmission route, not just a coincidental risk factor.

Why It Still Is Not Classified as an STI

If the evidence for sexual transmission is this strong, why not simply call it an STI? Because the bacterium also shows up in people who have never had sex, which classic STIs like chlamydia and gonorrhea essentially never do.

A study of adolescent females found no significant difference in the prevalence of BV or G. vaginalis between sexually active and virginal groups, leading the authors to conclude that BV “should not be considered an exclusively sexually transmitted disease.”⁹ In prepubertal children, G. vaginalis has been isolated from about 4% of those with no history of sexual abuse and no genitourinary complaints.¹⁰ A study of non-abused preschool children found G. vaginalis only in the anal canal and not in vaginal samples, suggesting the organism can colonize the gut as well.¹¹

These findings matter clinically. The presence of G. vaginalis in a child does not, on its own, indicate sexual abuse. And in adults, BV can develop through shifts in the vaginal microbiome triggered by factors other than sexual contact, including douching, antibiotic use, hormonal changes, and smoking. The bacterium exists as part of the vaginal ecosystem in many healthy, asymptomatic individuals with no symptoms and no BV diagnosis at all.

The Partner Treatment Puzzle

If BV were straightforwardly sexually transmitted, treating male partners should prevent reinfection. For decades, trials of male partner treatment showed no benefit, and guidelines reflected that. Then a landmark Australian trial published in the New England Journal of Medicine changed the conversation.

The StepUpRCT gave male sexual partners a combination of oral and topical antibiotics alongside standard treatment for the women. Among the women whose partners received treatment, BV recurred in about 35% within 12 weeks, compared with 63% in the group where only the women were treated.¹² That is a large and clinically meaningful difference, and it generated significant attention and hope.

However, a systematic review and meta-analysis pooling results across all randomized trials of male partner treatment found no significant overall reduction in BV recurrence compared with treating the woman alone.¹³ The discrepancy probably reflects differences in how the trials were designed, particularly which antibiotics were given, how they were administered, and whether they targeted the penile biofilm specifically. The StepUpRCT used a dual-antibiotic approach (oral plus penile topical) that earlier trials did not. If G. vaginalis hides in a penile biofilm, a single oral antibiotic may not reach it, which could explain why previous trials failed while the more aggressive approach succeeded.

This is exactly the kind of evidence that keeps BV in its taxonomic limbo. The partner treatment question has not been definitively settled, and until it is, guidelines will continue to hedge.

Not One Bacterium but Many

Part of the confusion around Gardnerella and BV stems from a major taxonomic revision that is still unfolding. What was long called a single species, Gardnerella vaginalis, turns out to be a complex of genetically distinct organisms. Whole-genome analysis of 81 Gardnerella genomes identified at least 13 genomic species within the genus, of which three were formally named as new species in 2019: G. leopoldii, G. piotii, and G. swidsinskii.¹⁴ Four more species have been formally described since then.¹⁵

This matters because not all Gardnerella species behave the same way. Some are strongly associated with BV symptoms and biofilm formation. Others appear to be harmless commensals that coexist peacefully with lactobacilli. When older studies found G. vaginalis in healthy women with no symptoms, they may have been detecting a benign species lumped under the same name as a pathogenic one. The clade research in WSW, mentioned earlier, hints at this: clade 4 was everywhere but rarely caused problems, while clade 1 was closely tied to disease. Until diagnostic tests can reliably distinguish between Gardnerella species, both research and clinical practice will be hampered by treating them as a single entity.

How G. Vaginalis Actually Causes Damage

The main weapon in the Gardnerella arsenal is a toxin called vaginolysin, a protein that punches holes in human cell membranes. Vaginolysin is considered the primary virulence factor of G. vaginalis, and it works by binding to cholesterol in cell membranes and forming pores that kill the cell.¹⁶ Interestingly, the toxin does not attack all surfaces equally. In lab models of vaginal tissue, vaginolysin damaged cells on the deeper, basolateral side of the epithelium but failed to penetrate the outermost layer of healthy vaginal cells.¹⁷ This suggests that G. vaginalis can grow on the vaginal surface without causing harm, but if it gets past the outer barrier through micro-abrasions, inflammation, or biofilm activity, it can trigger significant tissue damage.

When G. vaginalis does reach deeper tissue, it activates immune signaling pathways that lead to inflammation, including the release of inflammatory cytokines through a process that depends partly on a receptor called TLR2.¹⁸ That inflammation is a double-edged sword: it is part of the body’s defense, but chronic inflammation also makes the vaginal environment more hospitable to BV-associated bacteria and less hospitable to the protective lactobacilli that normally dominate.

There is even early evidence that statins, the cholesterol-lowering drugs, may interfere with vaginolysin’s ability to kill cells. Because vaginolysin depends on cholesterol to latch onto membranes, reducing cholesterol in vaginal cells made them more resistant to the toxin in laboratory experiments.¹⁹ Whether this has any real-world clinical relevance is unknown, but it illustrates how much the science of BV has shifted from viewing the condition as a simple infection to understanding it as a complex interaction between bacteria, host cells, and the local tissue environment.

Why BV Keeps Coming Back

For many people, the most frustrating aspect of BV is recurrence. Standard antibiotic treatment with metronidazole or clindamycin clears symptoms in most cases, but the infection returns within months for a substantial proportion of women. Biofilms are a major reason. The polymicrobial biofilm that forms in BV is difficult for antibiotics to fully penetrate, and even a small surviving pocket of bacteria can reseed the vaginal environment after treatment ends.²⁰

Reinfection from a sexual partner is another plausible driver, as the partner treatment data from the StepUpRCT suggests. And antibiotic-resistant strains add a third layer. The result is a condition where treatment failure does not mean the antibiotics were wrong, but that the infection has multiple escape routes that a single course of antibiotics cannot block simultaneously.

Probiotics and Emerging Prevention Strategies

Given the limitations of antibiotics alone, researchers have explored whether probiotics can help restore the vaginal microbiome and reduce BV recurrence. A systematic review found that Lactobacillus rhamnosus at high doses for 10 days was the most effective strain tested, improving clinical scores, lowering vaginal pH, and reducing recurrence rates. Other strains including L. crispatus, L. plantarum, and L. acidophilus also showed promise across various treatment durations.²¹

The idea is straightforward: if BV involves a collapse of the normal lactobacillus-dominated community, reintroducing those bacteria should help rebuild it. In practice, the results have been mixed. Probiotics seem to work best as an add-on to standard antibiotics rather than a replacement, and the optimal strains, doses, and delivery methods are still being worked out. Vaginal suppositories appear more promising than oral capsules for directly replenishing the vaginal community, but head-to-head comparisons remain limited.

Live biotherapeutics designed specifically for vaginal health are also in development. These go beyond off-the-shelf probiotic supplements by using strains selected for their ability to colonize the vagina, produce lactic acid and hydrogen peroxide, and outcompete BV-associated bacteria. None have achieved widespread clinical use yet, but they represent a fundamentally different approach from the antibiotic-treat-and-hope cycle that defines current management. For a condition so closely intertwined with the composition of an entire microbial community, therapies aimed at the community rather than at a single pathogen may ultimately prove more durable.

The Emotional Weight of a Blurry Diagnosis

The ambiguity around whether BV is sexually transmitted takes a real toll on people who live with it. Research into the lived experience of recurrent BV has found that women describe profound impacts on their emotional well-being, sexual relationships, and self-image.²² The smell associated with BV is a source of intense shame for many, and the uncertainty about whether they “caught” it from a partner or whether it arose on its own adds a layer of anxiety and suspicion that can corrode intimate relationships.

Clinicians sometimes dismiss BV as minor, which compounds the frustration. Patients are told it is not an STI, yet also told that sexual activity is a risk factor. They are treated with antibiotics that work temporarily, then left to manage recurring episodes with little explanation for why the infection returns. The lack of a clear category for BV, neither purely sexually transmitted nor purely endogenous, leaves patients without a coherent narrative for their own condition. Clearer communication from healthcare providers about what is and is not known, and an honest acknowledgment that the science is still catching up, can go a long way toward reducing the shame and confusion surrounding recurrent BV.